GoodRx Holdings, Inc. has no material assets or standalone operations other than its ownership in its consolidated subsidiaries. Under the terms of debt agreements entered into by GoodRx, a wholly-owned subsidiary of GoodRx

Intermediate Holdings, LLC, which itself is a wholly-owned subsidiary of GoodRx Holdings, Inc., GoodRx is restricted from making dividend payments, loans or advances to GoodRx Intermediate Holdings, LLC and GoodRx Holdings, Inc. These restrictions have resulted in the restricted net assets (as defined in Rule 1-02 of Regulation S-X) of GoodRx and its subsidiaries to exceed 25% of the consolidated net assets of GoodRx Holdings, Inc. and its subsidiaries.

The condensed financial information is presented on a “parent-only” basis, and GoodRx Holdings, Inc.’s investment in its subsidiary is stated at cost plus equity in loss of subsidiary less distributions received from subsidiary since the date of acquisition. GoodRx Holdings. Inc.’s share of net loss of its subsidiary is included in net loss using the equity method of accounting.


	December 31,
(in thousands, except par values)	2023		2022
Assets
Cash	$	5	$	5
Other assets	164		—
Investment in subsidiary, net of distributions	761,790		814,822
Total assets	$	761,959	$	814,827
Liabilities and stockholders' equity
Total liabilities	$	1	$	—
Stockholders' equity
Preferred stock, $0.0001 par value	—		—
Common stock, $0.0001 par value	40		40
Additional paid-in capital	2,219,321		2,263,322
Accumulated deficit	(1,457,403)		(1,448,535)
Total stockholders' equity	761,958		814,827
Total liabilities and stockholders' equity	$	761,959	$	814,827


	Year Ended December 31,
(in thousands)	2023		2022		2021
Cash flows from operating activities
Net loss	$	(8,868)	$	(32,828)	$	(25,254)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Equity in loss of subsidiary	8,868		32,828		25,254
Changes in assets and liabilities:
Other assets	(164)		80		(23)
Other current liabilities	1		—		(87)
Net cash (used in) provided by operating activities	(163)		80		(110)
Cash flows from investing activities
Distribution from subsidiary	162,287		113,117		22,777
Net cash provided by investing activities	162,287		113,117		22,777
Cash flows from financing activities
Repurchases of Class A common stock	(103,974)		(101,721)		—
Proceeds from exercise of stock options	5,941		9,159		35,021
Employee taxes paid related to net share settlement of equity awards	(65,481)		(20,635)		(57,688)
Proceeds from employee stock purchase plan	1,390		—		—
Net cash used in financing activities	(162,124)		(113,197)		(22,667)
Net change in cash	—		—		—
Cash
Beginning of period	5		5		5
End of period	$	5	$	5	$	5